The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma

被引:20
作者
Zhang, Pengpeng [1 ]
Pei, Shengbin [2 ]
Gong, Zeitian [1 ]
Ren, Qianhe [1 ]
Xie, Jiaheng [3 ]
Liu, Hong [4 ]
Wang, Wei [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Breast Surg, Nanjing, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Burns & Plast Surg, Nanjing, Peoples R China
[4] Second Hosp Nanjing, Dept Thorac Surg, Nanjing, Peoples R China
关键词
lung adenocarcinoma; lactate; signature; prognosis; immunotherapy; CANCER; BLOCKADE;
D O I
10.3389/fendo.2023.1154410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundIt has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. MethodsThe most significant genes for LM were identified through the use of the AUCell algorithm and correlation analysis in conjunction with scRNA-seq analysis. To build risk models with superior predictive performance, cox- and lasso-regression were utilized, and these models were validated on multiple external independent datasets. We then explored the differences in the tumor microenvironment (TME), immunotherapy, mutation landscape, and enriched pathways between different risk groups. Finally, cell experiments were conducted to verify the impact of AHSA1 in LUAD. ResultsA total of 590 genes that regulate LM were identified for subsequent analysis. Using cox- and lasso-regression, we constructed a 5-gene signature that can predict the prognosis of patients with LUAD. Notably, we observed differences in TME, immune cell infiltration levels, immune checkpoint levels, and mutation landscapes between different risk groups, which could have important implications for the clinical treatment of LUAD patients. ConclusionBased on LMRGs, we constructed a prognostic model that can predict the efficacy of immunotherapy and provide a new direction for treating LUAD.
引用
收藏
页数:18
相关论文
共 22 条
[1]   Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].
Aberle, Denise R. ;
Adams, Amanda M. ;
Berg, Christine D. ;
Black, William C. ;
Clapp, Jonathan D. ;
Fagerstrom, Richard M. ;
Gareen, Ilana F. ;
Gatsonis, Constantine ;
Marcus, Pamela M. ;
Sicks, JoRean D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409
[2]   Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].
Anagnostou, Valsamo ;
Smith, Kellie N. ;
Forde, Patrick M. ;
Niknafs, Noushin ;
Bhattacharya, Rohit ;
White, James ;
Zhang, Theresa ;
Adleff, Vilmos ;
Phallen, Jillian ;
Wali, Neha ;
Hruban, Carolyn ;
Guthrie, Violeta B. ;
Rodgers, Kristen ;
Naidoo, Jarushka ;
Kang, Hyunseok ;
Sharfman, William ;
Georgiades, Christos ;
Verde, Franco ;
Illei, Peter ;
Li, Qing Kay ;
Gabrielson, Edward ;
Brock, Malcolm V. ;
Zahnow, Cynthia A. ;
Baylin, Stephen B. ;
Scharpf, Robert B. ;
Brahmer, Julie R. ;
Karchin, Rachel ;
Pardoll, Drew M. ;
Velculescu, Victor E. .
CANCER DISCOVERY, 2017, 7 (03) :264-276
[3]   Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with in vivo and vitro validation [J].
Chen, Xu ;
Yuan, Qihang ;
Liu, Jifeng ;
Xia, Shilin ;
Shi, Xueying ;
Su, Yuxin ;
Wang, Zhizhou ;
Li, Shuang ;
Shang, Dong .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[4]   Replication stress and cancer [J].
Gaillard, Helene ;
Garcia-Muse, Tatiana ;
Aguilera, Andres .
NATURE REVIEWS CANCER, 2015, 15 (05) :276-289
[5]   Why do cancers have high aerobic glycolysis? [J].
Gatenby, RA ;
Gillies, RJ .
NATURE REVIEWS CANCER, 2004, 4 (11) :891-899
[6]   The National Lung Screening Trial: Overview and Study Design [J].
Gatsonis, Constantine A. .
RADIOLOGY, 2011, 258 (01) :243-253
[7]   The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].
Goldstraw, Peter ;
Chansky, Kari ;
Crowley, John ;
Rami-Porta, Ramon ;
Asamura, Hisao ;
Eberhardt, Wilfried E. E. ;
Nicholson, Andrew G. ;
Groome, Patti ;
Mitchell, Alan ;
Bolejack, Vanessa .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51
[8]   The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment [J].
Hayes, Conall ;
Donohoe, Claire L. ;
Davern, Maria ;
Donlon, Noel E. .
CANCER LETTERS, 2021, 500 :75-86
[9]   Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis [J].
Ishikawa, Masashi ;
Iwasa, Satoru ;
Nagashima, Kengo ;
Aoki, Masahiko ;
Imazeki, Hiroshi ;
Hirano, Hidekazu ;
Shoji, Hirokazu ;
Honma, Yoshitaka ;
Okita, Natsuko ;
Takashima, Atsuo ;
Kato, Ken ;
Saruta, Masayuki ;
Boku, Narikazu .
INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) :533-540
[10]   Phenotype molding of stromal cells in the lung tumor microenvironment [J].
Lambrechts, Diether ;
Wauters, Els ;
Boeckx, Bram ;
Aibar, Sara ;
Nittner, David ;
Burton, Oliver ;
Bassez, Ayse ;
Decaluwe, Herbert ;
Pircher, Andreas ;
Van den Eynde, Kathleen ;
Weynand, Birgit ;
Verbeken, Erik ;
De Leyn, Paul ;
Liston, Adrian ;
Vansteenkiste, Johan ;
Carmeliet, Peter ;
Aerts, Stein ;
Thienpont, Bernard .
NATURE MEDICINE, 2018, 24 (08) :1277-+